Captrust Financial Advisors Increases Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Captrust Financial Advisors lifted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 20.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,988 shares of the company’s stock after buying an additional 340 shares during the quarter. Captrust Financial Advisors’ holdings in TransMedics Group were worth $312,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Amalgamated Bank grew its holdings in TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares during the period. Harbour Capital Advisors LLC grew its stake in shares of TransMedics Group by 1.7% in the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after buying an additional 81 shares during the last quarter. Signaturefd LLC raised its stake in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares during the last quarter. Arizona State Retirement System boosted its holdings in TransMedics Group by 2.1% in the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after acquiring an additional 186 shares in the last quarter. Finally, Venturi Wealth Management LLC grew its stake in shares of TransMedics Group by 33.7% in the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after acquiring an additional 219 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TMDX has been the subject of several recent analyst reports. Canaccord Genuity Group lowered their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Piper Sandler reduced their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday. Finally, Robert W. Baird cut their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $126.80.

Insider Buying and Selling at TransMedics Group

In other news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,089,766.32. The trade was a 12.43 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,042 shares of company stock valued at $3,563,985. Insiders own 7.00% of the company’s stock.

TransMedics Group Stock Performance

Shares of TMDX opened at $64.26 on Friday. The firm has a market capitalization of $2.16 billion, a P/E ratio of 68.36 and a beta of 2.06. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group, Inc. has a one year low of $63.42 and a one year high of $177.37. The business has a fifty day moving average of $95.77 and a 200 day moving average of $131.37.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the previous year, the business posted ($0.12) earnings per share. The company’s revenue for the quarter was up 63.7% on a year-over-year basis. As a group, sell-side analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.